Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
vi. lappuse
... meet the requirement to publish regu- lations in the Federal Register by referring to materials already published else- where . For an incorporation to be valid , the Director of the Federal Register must approve it . The legal effect ...
... meet the requirement to publish regu- lations in the Federal Register by referring to materials already published else- where . For an incorporation to be valid , the Director of the Federal Register must approve it . The legal effect ...
7. lappuse
... meet the appropriate criteria listed in paragraph ( a ) of this section . ( c ) A fixed - combination prescription drug for humans that has been deter- mined to be effective for labeled indica- tions by the Food and Drug Adminis ...
... meet the appropriate criteria listed in paragraph ( a ) of this section . ( c ) A fixed - combination prescription drug for humans that has been deter- mined to be effective for labeled indica- tions by the Food and Drug Adminis ...
13. lappuse
... meet their professed standards of identity , strength , quality , and purity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not ...
... meet their professed standards of identity , strength , quality , and purity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not ...
14. lappuse
... meet- ing all the following conditions : ( i ) The sodium gentisate is prepared , with or without other drugs , in tablet or other dosage form suitable for oral use in self - medication , and containing no drug limited to prescription ...
... meet- ing all the following conditions : ( i ) The sodium gentisate is prepared , with or without other drugs , in tablet or other dosage form suitable for oral use in self - medication , and containing no drug limited to prescription ...
15. lappuse
... meet their professed standards of identity , strength , quality , and pu- rity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not ...
... meet their professed standards of identity , strength , quality , and pu- rity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning